香蕉短视频安卓在哪下载 香蕉短视频安卓在哪下载 ,m1938a 在线观看 m1938a 在线观看

发布日期:2021年06月16日
 

WHO WE ARE

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).

Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

VIFOR PHARMA GROUP COMPANIES

Vifor Pharma

Vifor Pharma is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as non-prescription medicines.

Vifor Pharma’s operational headquarters are in Zurich, Switzerland, and the company has an increasingly global presence and a broad network of affiliates and partners around the world.

Key brands in the iron treatment portfolio are intravenous products, Ferinject® and Venofer®, and oral product, Maltofer®

Vifor Fresenius Medical Care Renal Pharma

Our presence in the global nephrology market is primarily built around the joint company Vifor Fresenius Medical Care Renal Pharma (VFMCRP), which combines Vifor Pharma’s expertise in pharmaceuticals with the skills and infrastructure of Fresenius Medical Care. Fresenius Medical Care has access to more than 345,000 patients in its global network of around 4,000 dialysis clinics, and is the world’s leading provider of products and services for people with chronic kidney failure. The joint company’s objective is to provide a portfolio of products and innovative services addressing the major therapeutic needs of CKD patients. These include renal anaemia management, mineral and bone disease management, kidney function preservation and improvement, CKD-associated complications and cardio-renal management including hyperkalaemia and iron deficiency.